

07.03.2022

08:00 - 09:00 e-Poster Display session

Channel 1

08:00 - 08:20 **Antibody-based therapies**08:20 - 08:40 **1P - Sitravatinib + Tislelizumab in Patients with Anti-PD-(L)1 Refractory/Resistant Metastatic Non-small Cell Lung Cancer (NSCLC)**

B. Gao<sup>1</sup>, Z. Ma<sup>2</sup>, X. Yu<sup>3</sup>, D. Huang<sup>4</sup>, J. Zhao<sup>5</sup>, D. Day<sup>6</sup>, A. Body<sup>6</sup>, Q. Zhou<sup>7</sup>, Q. Chu<sup>8</sup>, H. Pan<sup>9</sup>, J. Cui<sup>10</sup>, H. Li<sup>11</sup>, J. Sun<sup>11</sup>, J. Zhang<sup>11</sup>, C. Fei<sup>11</sup>, Y.-L. Wu<sup>12</sup>, <sup>1</sup>Blacktown Cancer and Hematology Centre, Blacktown, AU, <sup>2</sup>The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, <sup>3</sup>Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, CN, <sup>4</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>5</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>6</sup>Monash Health and Monash University, Melbourne, AU, <sup>7</sup>Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>8</sup>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>9</sup>Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, <sup>10</sup>The First Hospital of Jilin University, Changchun, CN, <sup>11</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>12</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, CN

08:40 - 09:00 **2P - Sitravatinib + Tislelizumab in Patients with Metastatic Non-small Cell Lung Cancer (NSCLC)**

Q. Zhou<sup>1</sup>, X. Yu<sup>2</sup>, B. Gao<sup>3</sup>, Z. Ma<sup>4</sup>, Q. Chu<sup>5</sup>, D. Huang<sup>6</sup>, J. Zhao<sup>7</sup>, D. Day<sup>8</sup>, A. Body<sup>8</sup>, H. Pan<sup>9</sup>, J. Cui<sup>10</sup>, H. Li<sup>11</sup>, J. Sun<sup>11</sup>, J. Zhang<sup>11</sup>, C. Fei<sup>11</sup>, Y.-L. Wu<sup>12</sup>, <sup>1</sup>Guangdong Lung Cancer Institute, Guangdong General Hospital, and Guangdong Academy of Medical Sciences, Guangzhou, CN, <sup>2</sup>Cancer Hospital of University of Chinese Academy of Sciences & Zhejiang Cancer Hospital, Hangzhou, CN, <sup>3</sup>Blacktown Cancer and Hematology Centre, Blacktown, AU, <sup>4</sup>The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, CN, <sup>5</sup>Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, <sup>6</sup>Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN, <sup>7</sup>Peking University Cancer Hospital & Institute, Beijing, CN, <sup>8</sup>Monash Health and Monash University, Melbourne, AU, <sup>9</sup>Sir Run Run Shaw Hospital, Zhejiang University, Hangzhou, CN, <sup>10</sup>The First Hospital of Jilin University, Changchun, CN, <sup>11</sup>BeiGene (Beijing) Co., Ltd., Beijing, CN, <sup>12</sup>Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, South China University of Technology, Guangzhou, CN

09:00 - 09:20 **3P - Targeting pancreatic adenocarcinoma upregulated factor (PAUF) to treat pancreatic cancer (PC): In vivo efficacy and safety of PBP1510, a first in class monoclonal antibody (mAb)**

S. Pradhan<sup>1</sup>, Y.J. Kim<sup>2</sup>, J. Park<sup>3</sup>, S.-Y. Jeong<sup>3</sup>, S.S. Koh<sup>2</sup>, K.D. Mandakhalikar<sup>2</sup>, J. Kim<sup>2</sup>, L. Jaison<sup>2</sup>, <sup>1</sup>Prestige BioPharma Pte. Ltd., Singapore, SG, <sup>2</sup>Prestige Biopharma Limited, Singapore, SG, <sup>3</sup>University of Ulsan College of Medicine, Seoul, KR

- 09:20 - 09:40 **4P - Antitumor efficacy of integrin  $\alpha$ V $\beta$ 3 Antibody conjugated ZnO Nanocarrier based Drug Delivery System to target Breast carcinoma**  
K. Vimala, S. Kannan, Periyar University, Salem, IN
- 09:40 - 10:00 **DNA damage repair**
- 10:00 - 10:20 **8P - Pharmacokinetic (PK) profile and food effect of RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase in patients (pts) with cancer**  
S. Lheureux<sup>1</sup>, E. Rosen<sup>2</sup>, E. Lee<sup>3</sup>, D. Spigel<sup>4</sup>, M. Højgaard<sup>5</sup>, E. Fontana<sup>6</sup>, N. Mettu<sup>7</sup>, L. Carter<sup>8</sup>, S. Patel<sup>9</sup>, R. Papp<sup>9</sup>, S. May<sup>9</sup>, P. Nejad<sup>9</sup>, D. Ulanet<sup>9</sup>, M. Wainszelbaum<sup>9</sup>, P. Manley<sup>9</sup>, M. Koehler<sup>9</sup>, A. Fretland<sup>9</sup>, R. Plummer<sup>10</sup>, T. Yap<sup>11</sup>, <sup>1</sup>University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>2</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>3</sup>Dana-Farber Cancer Institute, Boston, US, <sup>4</sup>Sarah Cannon Research Institute, Nashville, US, <sup>5</sup>Rigshospitalet, Copenhagen, DK, <sup>6</sup>Sarah Cannon Research Institute UK, London, GB, <sup>7</sup>Duke University Medical Center, Durham, US, <sup>8</sup>Institution The Christie NHS Foundation Trus, Manchester, GB, <sup>9</sup>Repare Therapeutics, Cambridge, US, <sup>10</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>11</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US
- 10:20 - 10:40 **9P - Preliminary population pharmacokinetic (popPK) co-variates and exposure response (ER) assessment of QT for RP-3500, a highly potent and specific inhibitor of ataxia telangiectasia and Rad3-related (ATR) protein kinase**  
E. Lee<sup>1</sup>, T. Yap<sup>2</sup>, E. Fontana<sup>3</sup>, E. Rosen<sup>4</sup>, D. Spigel<sup>5</sup>, S. Lheureux<sup>6</sup>, N. Mettu<sup>7</sup>, L. Carter<sup>8</sup>, R. Plummer<sup>9</sup>, S. Patel<sup>10</sup>, R. Mcdougall<sup>10</sup>, R. Papp<sup>10</sup>, S. May<sup>10</sup>, P. Nejad<sup>10</sup>, D. Ulanet<sup>10</sup>, M. Wainszelbaum<sup>10</sup>, P. Manley<sup>10</sup>, M. Koehler<sup>10</sup>, A. Fretland<sup>10</sup>, M. Højgaard<sup>11</sup>, <sup>1</sup>Dana-Farber Cancer Institute, Boston, US, <sup>2</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>3</sup>Sarah Cannon Research Institute UK, London, GB, <sup>4</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>5</sup>Sarah Cannon Research Institute, Nashville, US, <sup>6</sup>University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>7</sup>Duke University Medical Center, Durham, US, <sup>8</sup>Institution The Christie NHS Foundation Trus, Manchester, GB, <sup>9</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>10</sup>Repare Therapeutics, Cambridge, US, <sup>11</sup>Rigshospitalet, Copenhagen, DK
- 10:40 - 11:00 **Epigenetics**
- 11:00 - 11:20 **10P - SKLB-0322, a novel EZH2 covalent inhibitor, exerts potent anti-tumor activity in ovarian cancer**  
Y. Zhu<sup>1</sup>, X. Chen<sup>2</sup>, Q. Zhang<sup>3</sup>, J. Zeng<sup>3</sup>, H. Xiao<sup>4</sup>, L. Yu<sup>3</sup>, <sup>1</sup>Hennan Provincial Peoples' Hospital, Zhengzhou, CN, <sup>2</sup>est China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Cheng Du, CN, <sup>3</sup>West China Hospital, and Collaborative Innovation Center of Biotherapy, Sichuan University, Cheng Du, CN, <sup>4</sup>Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Cheng Du, CN

- 11:20 - 11:40 **11P - Novel HDAC6 inhibitors show anti-lymphoma activity alone and in combination with venetoclax and copanlisib**  
A. Mensah<sup>1</sup>, G. Sartori<sup>1</sup>, C. Falzarano<sup>1</sup>, W. Tueckmantel<sup>2</sup>, A. Kozikowski<sup>2</sup>, F. Bertoni<sup>1</sup>,  
<sup>1</sup>IOR - Institute of Oncology Research, Bellinzona, CH, <sup>2</sup>Bright Minds Biosciences, New York, US
- 11:40 - 12:00 **12P - Circulating tumor DNA as early marker of response to treatment in stage IV gastrointestinal cancer**  
P. Kirchweiger<sup>1</sup>, A. Kupferthaler<sup>1</sup>, J. Burghofer<sup>1</sup>, G. Webersinke<sup>1</sup>, E. Jukic<sup>2</sup>, S. Schwendinger<sup>2</sup>, R. Függer<sup>1</sup>, M. Biebl<sup>1</sup>, H. Wundsam<sup>1</sup>, H. Rumpold<sup>1</sup>, <sup>1</sup>Ordensklinikum Linz Barmherzige Schwestern, Linz, AT, <sup>2</sup>Medical University of Innsbruck, Innsbruck, AT
- 12:00 - 12:20 **13P - Transcriptional Profiling of FET-rearranged sarcomas in response to SP-2577**  
G. Rask<sup>1</sup>, E. Theisen<sup>1</sup>, A. Duncan<sup>2</sup>, D. Santiesteban<sup>2</sup>, <sup>1</sup>Nationwide Children's Hospital, Columbus, US, <sup>2</sup>Salarius Pharmaceuticals, Houston, US
- 12:20 - 12:40 **14P - A novel small molecule METTL3 inhibitor exerts promising antitumor effects on oral squamous cell carcinoma**  
P. Arumugam, V. Jayaseelan, Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, IN
- 12:40 - 13:00 **Immunotherapy**
- 13:00 - 13:20 **15P - STELLAR-001: a phase 1 study of the anti-C5aR avdoralimab in combination with the anti-PD-L1 durvalumab in advanced solid tumors.**  
J. Bennouna<sup>1</sup>, Y. Touchefeu<sup>2</sup>, F. Ghiringhelli<sup>3</sup>, N. Isambert<sup>3</sup>, F. Barlesi<sup>4</sup>, P. Tomasini<sup>3</sup>, P. Cassier<sup>5</sup>, J. Edeline<sup>6</sup>, S. Le Sourd<sup>6</sup>, D. Tosi<sup>7</sup>, A. Tolcher<sup>8</sup>, T. Marron<sup>9</sup>, D. Marie<sup>10</sup>, J. Viotti<sup>10</sup>, A. Boyer Chammard<sup>10</sup>, P. Martin Romano<sup>11</sup>, C. Massard<sup>4</sup>, <sup>1</sup>Hopital Foch, Suresnes, FR, <sup>2</sup>CHU du Nantes - Hôtel-Dieu, Nantes, Cedex 1, FR, <sup>3</sup>Centre Georges-François Leclerc (Dijon), Dijon, FR, <sup>4</sup>Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>5</sup>Centre Léon Bérard, Lyon, FR, <sup>6</sup>Centre Eugene - Marquis, Rennes, FR, <sup>7</sup>ICM - Institut du Cancer de Montpellier, Montpellier, Cedex 5, FR, <sup>8</sup>NEXT OncologyTM, San Antonio, US, <sup>9</sup>The Mount Sinai Hospital - Icahn School of Medicine, New York, US, <sup>10</sup>Innate Pharma, Marseille, FR, <sup>11</sup>Institut Gustave Roussy, Villejuif, Cedex, FR
- 13:20 - 13:40 **16P - Checkpoint modification of BTLA-HVEM-LIGHT signaling by HSV-1 glycoprotein D (gD) improves vaccine-induced CD8+ T cell responses in pre-clinical cancer models**  
A. Luber<sup>1</sup>, X. Zhou<sup>2</sup>, Z. Xiang<sup>2</sup>, W. Giles-Davis<sup>2</sup>, C. Magowan<sup>1</sup>, H. Ertl<sup>2</sup>, <sup>1</sup>Virion Therapeutics, Newark, US, <sup>2</sup>The Wistar Institute, Philadelphia, US
- 13:40 - 14:00 **17P - Driving NK cell immunotherapy against NSCLC, in the context of hypoxia, using tri-specific engagers**  
J. Miller<sup>1</sup>, M. Felices<sup>2</sup>, D. Vallera<sup>2</sup>, B. Ettestad<sup>2</sup>, C. Hallstrom<sup>2</sup>, B. Kodala<sup>2</sup>, D. Todhunter<sup>2</sup>, U. Arvindam<sup>2</sup>, S. Phung<sup>2</sup>, Q. Kile<sup>2</sup>, G. Berk<sup>3</sup>, P. Kennedy<sup>2</sup>, <sup>1</sup>Masonic Cancer Center -

University of Minnesota, Minneapolis, US, <sup>2</sup>University of Minnesota, Minneapolis, US,  
<sup>3</sup>GT Biopharma, Beverly Hill, US

- 14:00 - 14:20 **18P - Baseline and dynamic changes in haemoglobin levels predict treatment response and disease progression in metastatic renal cell carcinoma**  
Y.-H. Yang<sup>1</sup>, A. Meerveld-Eggink<sup>2</sup>, A. Bex<sup>3</sup>, F. Jackson-Spence<sup>4</sup>, K. Rallis<sup>5</sup>, P. Brian<sup>6</sup>, J. Choy<sup>7</sup>, C. Sng<sup>8</sup>, P. Adeniran<sup>6</sup>, J. Amin<sup>6</sup>, S. Galope<sup>6</sup>, N. Anderson<sup>6</sup>, S. Fernandezgomez<sup>6</sup>, T. Powles<sup>4</sup>, B. Szabados<sup>7</sup>, <sup>1</sup>National Health Service - UK, Birmingham, GB, <sup>2</sup>NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, <sup>3</sup>Royal Free London NHS Foundation Trust, London, GB, <sup>4</sup>St. Bartholomew's Hospital - Barts Health NHS Trust, London, GB, <sup>5</sup>QMUL, London, GB, <sup>6</sup>Barts Health NHS Trust, London, GB, <sup>7</sup>Cancer Research UK Barts Centre - Barts and The London School of Medicine and Dentistry, London, GB, <sup>8</sup>University College London Hospitals NHS Foundation Trust, London, GB
- 14:20 - 14:40 **19P - Tumor retargeting universal chimeric antigen receptor T cell (TRUE-CAR T) therapy in solid tumors**  
F. Meng<sup>1</sup>, Z. Sun<sup>2</sup>, B. Liu<sup>2</sup>, <sup>1</sup>Affiliated Drum Tower Hospital Nanjing University, Nanjing, CN, <sup>2</sup>The Comprehensive Cancer Center of Drum Tower Hospital, Nanjing, CN
- 14:40 - 15:00 **20P - Immuno-modulating effects of hyperthermia on PD-L1 and NLRC5 in ovarian cancer**  
M. Fezza<sup>1</sup>, G. Hilal<sup>1</sup>, R. Tahtouh<sup>1</sup>, D. Atallah<sup>2</sup>, <sup>1</sup>Saint Joseph University - Faculty of Medicine, Beirut, LB, <sup>2</sup>Saint Joseph University - Faculty of Medicine, beirut, LB
- 15:00 - 15:20 **21P - Transcriptomic mapping of integrins and immune activation in High- Grade Serous Ovarian Cancer.**  
K. Rojas Laimito<sup>1</sup>, A. Ocana Fernandez<sup>2</sup>, M.V. Villena<sup>3</sup>, J.L. Gonzalez L.<sup>4</sup>, J. Puente V.<sup>4</sup>, M.J. Rubio<sup>5</sup>, H. García-Martínez<sup>6</sup>, J. Garcia-Donas<sup>7</sup>, L. Manso S.<sup>3</sup>, <sup>1</sup>University Hospital 12 De Octubre, Madrid, ES, <sup>2</sup>Hospital Clinico Universitario San Carlos, Madrid, ES, <sup>3</sup>Hospital Universitario 12 de Octubre, Madrid, ES, <sup>4</sup>Hospital Clínico San Carlos (HCSC), Instituto de Investigación Sanitaria (IdISSC) and CIBERONC, Madrid, ES, <sup>5</sup>University Hospital Reina Sofia, Cordoba, ES, <sup>6</sup>Hospital Morales Meseguer, Murcia, ES, <sup>7</sup>Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES
- 15:20 - 15:40 **22P - Active immunization with a multi-peptide B cell vaccine, targeting Trastuzumab and Pertuzumab binding sites, prevents the formation of Her-2/neu expressing lung metastases**  
J. Tobias<sup>1</sup>, M. Drinić<sup>2</sup>, S. Högler<sup>3</sup>, A. Schmid<sup>2</sup>, E. Garner-Spitzer<sup>2</sup>, L. Kenner<sup>2</sup>, M. Kundi<sup>2</sup>, C. Zielinski<sup>2</sup>, U. Wiedermann<sup>2</sup>, <sup>1</sup>Studienabteilung der Medizinische Universität Wien, Vienna, AT, <sup>2</sup>Medical University of Vienna, Vienna, AT, <sup>3</sup>University of Veterinary Medicine, Vienna, AT
- 15:40 - 16:00 **23P - Engineered chemotherapy resistant  $\gamma\delta$  T-cells with combinatorial chemotherapies can enhance tumor cell immunogenicity and killing**  
K. Rochlin<sup>1</sup>, A. Jones<sup>2</sup>, L. Ding<sup>1</sup>, L. Lamb<sup>3</sup>, A. Hjelmeland<sup>2</sup>, <sup>1</sup>IN8bio, New York, US, <sup>2</sup>University of Alabama Birmingham, Birmingham, US, <sup>3</sup>Incysus Therapeutics, Inc., Birmingham, US

- 16:00 - 16:20 **24P - Evidence for synergy between TNG908, an MTAPnull-selective PRMT5 inhibitor, and sotorasib in an MTAPnull/KRASG12C xenograft model**  
K. Briggs, G. Corriea, A. Tsai, M. Zhang, M. Tonini, E. Wilker, C. Davis, K. Cottrell, J. Maxwell, A. Huang, Tango Therapeutics, Inc., Cambridge, US
- 16:20 - 16:40 **25P - Impact of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma (the MEMOIR study): a propensity score-matched analysis**  
D. Qian<sup>1</sup>, T. Kleber<sup>2</sup>, B. Brammer<sup>2</sup>, K. Xu<sup>2</sup>, J. Switchenko<sup>3</sup>, J. Janopaul-Naylor<sup>2</sup>, J. Zhong<sup>2</sup>, M. Yushak<sup>2</sup>, R.D. Harvey<sup>2</sup>, C. Paulos<sup>2</sup>, D. Lawson<sup>2</sup>, M. Khan<sup>2</sup>, R. Kudchadkar<sup>2</sup>, Z. Buchwald<sup>2</sup>, <sup>1</sup>Emory University, Atlanta, US, <sup>2</sup>Emory University School of Medicine, Atlanta, US, <sup>3</sup>Rollins School of Public Health of Emory University, Atlanta, US
- 16:40 - 17:00 **Kinase-targeting agents and cell signalling modulators**
- 17:00 - 17:20 **28P - Discovery of Potent PROTAC Degradors of KRASG12C Based on a Reversible Non-covalent KRAS Binder**  
Z. Zhang, W. Zhai, H. Chen, L. Wang, D. Liu, Huadong Medicine, Hangzhou, CN
- 17:20 - 17:40 **29P - LIBRETTO-321, a phase 2 study of the efficacy and safety of selpercatinib in Chinese patients with advanced RET-altered thyroid cancer (TC)**  
X. Zheng<sup>1</sup>, Q. Ji<sup>2</sup>, Y. Sun<sup>3</sup>, M. Ge<sup>4</sup>, B. Zhang<sup>5</sup>, Y. Cheng<sup>6</sup>, S. Lei<sup>7</sup>, F. Shi<sup>8</sup>, W. Zhang<sup>9</sup>, M. Gao<sup>1</sup>, <sup>1</sup>Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, CN, <sup>2</sup>Fudan University Shanghai Cancer Center, Shanghai, CN, <sup>3</sup>Jinan Central Hospital Affiliated to Shandong University, Jinan, CN, <sup>4</sup>Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, CN, <sup>5</sup>Peking University Cancer Hospital and Institute, Beijing, CN, <sup>6</sup>Jilin Cancer Hospital, Changchun, CN, <sup>7</sup>Nanfang Hospital, Southern Medical University, Guangzhou, CN, <sup>8</sup>The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, and Hunan Cancer Hospital, Changsha, CN, <sup>9</sup>Eli Lilly and Company, Shanghai, CN
- 17:40 - 18:00 **30P - Comparative biochemical and cellular profiling of kinase inhibitors approved for clinical use from 2018 to 2020**  
J. Kooijman<sup>1</sup>, W. Van Riel<sup>2</sup>, M. Prinsen<sup>3</sup>, J. Dylus<sup>1</sup>, Y. Grobber<sup>1</sup>, J. De Roos<sup>1</sup>, J. Melis<sup>1</sup>, T. De Bitter<sup>1</sup>, Y. Narumi<sup>4</sup>, Y. Kawase<sup>4</sup>, N. Willemsen-Seegers<sup>1</sup>, G. Zaman<sup>2</sup>, <sup>1</sup>Oncolines BV, Oss, NL, <sup>2</sup>NTRC B.V., Oss, NL, <sup>3</sup>NTRC Therapeutics BV, Oss, NL, <sup>4</sup>Carna Biosciences, Inc., Kobe, JP
- 18:00 - 18:20 **31P - Molecular testing, treatment and outcome of patients with advanced solid tumors harboring a NTRK1, NTRK2 or NTRK3 gene fusion - Study design and first results of the REALTRK registry**  
C. Vannier<sup>1</sup>, A. Völkel<sup>2</sup>, U.M. Martens<sup>3</sup>, T. Decker<sup>4</sup>, G. Köchling<sup>5</sup>, S. Lange<sup>6</sup>, E. Von Der Heyde<sup>7</sup>, T.-O. Emde<sup>8</sup>, A. Wortmann<sup>9</sup>, R. Grunewald<sup>10</sup>, M. Frank<sup>11</sup>, B. Niemeier<sup>1</sup>, M.

Flum<sup>11</sup>, B. Kasenda<sup>11</sup>, <sup>1</sup>iOMEDICO AG, Freiburg im Breisgau, DE, <sup>2</sup>Praxis für interdisziplinäre Onkologie und Hämatologie, Freiburg, DE, <sup>3</sup>SLK-Kliniken Heilbronn GmbH, Heilbronn, DE, <sup>4</sup>Onkologie Hamatologie Ravensburg, Ravensburg, DE, <sup>5</sup>Onkologie Schwarzwald-Alb, Villingen-Schwenningen, DE, <sup>6</sup>TUM - Technical University of Munich, Munich, DE, <sup>7</sup>Onkologische Schwerpunktpraxis, Hannover, DE, <sup>8</sup>Praxis und Tagesklinik für Internistische Onkologie und Hämatologie, Recklinghausen, DE, <sup>9</sup>OnkologieZentrum Soest-Iserlohn - Schwerpunktpraxis für Hämatologie und Onkologie, Soest, DE, <sup>10</sup>Centrum für Hämatologie und Onkologie Bethanien, Frankfurt am Main, DE, <sup>11</sup>iOMEDICO AG, Freiburg, DE

18:20 - 18:40

**32P - Anlotinib enhances the antitumor activity of high dose irradiation combined with anti PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer**

M. Yuan<sup>1</sup>, Y. Zhai<sup>2</sup>, Z. Hui<sup>2</sup>, <sup>1</sup>Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, <sup>2</sup>National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

18:40 - 19:00

**33P - Synergistic effects of Alpelisib (PI3K inhibitor) and Ribociclib (CDK 4/6 inhibitor) in preclinical colorectal cancer (CRC) models**

R. Aslam<sup>1</sup>, S. Toomey<sup>2</sup>, B. Hennessy<sup>3</sup>, <sup>1</sup>RCSI Education & Research Centre, Beaumont Hospital, Dublin, IE, <sup>2</sup>RCSI Molecular Medicine Laboratories, Dublin, IE, <sup>3</sup>Beaumont Hospital, Dublin, IE

19:00 - 19:20

**34P - Efficacy and toxicity analysis of Imatinib in Newly Diagnosed Patients of Chronic Myeloid Leukaemia: 18-years' experience at a single large-volume centre.**

R. Yadav<sup>1</sup>, S. Parikh<sup>2</sup>, H. Panchal<sup>2</sup>, A. Patel<sup>2</sup>, A. Garg<sup>2</sup>, K. Shah<sup>2</sup>, P. Basu<sup>2</sup>, V. Patel<sup>1</sup>, S.R. Ganta<sup>2</sup>, S. Ravichandran<sup>2</sup>, D. Banerjee<sup>2</sup>, <sup>1</sup>Gujarat Cancer Research Institute, Ahmedabad, IN, <sup>2</sup>Gujarat Cancer Research Institute, AHMEDABAD, IN

19:20 - 19:40

**35P - NSCLC- Real world data analysis from a chain of Oncology centres in Western India**

A. Shivchhand<sup>1</sup>, A. Joshi<sup>2</sup>, U. Maheshwari<sup>2</sup>, V. Maniar<sup>2</sup>, K. Joshi<sup>2</sup>, P. Kalaskar<sup>3</sup>, S. Sheth<sup>3</sup>, P. Kendre<sup>2</sup>, R. Korgavkar<sup>2</sup>, D. Morzaria<sup>2</sup>, C. Pethe<sup>4</sup>, S. Dhande<sup>4</sup>, M. Mekha<sup>5</sup>, D. Rane<sup>2</sup>, S. Jagiasi<sup>2</sup>, <sup>1</sup>Apple Cancer Institute, Kolhapur, IN, <sup>2</sup>Mumbai OncoCare Centre, Mumbai, IN, <sup>3</sup>Mumbai OncoCare Centre, Thane, IN, <sup>4</sup>Mumbai OncoCare Centre, Nashik, IN, <sup>5</sup>Mumbai OncoCare Centre, Pune, IN

19:40 - 20:00

**36P - A point mutation replacing Cysteine with Arginine at position 382 (C382R) in the transmembrane domain of FGFR2 leads to response to FGF2-inhibitor Pemigatinib in chemo-refractory intrahepatic cholangiocarcinoma**

L. Hempel<sup>1</sup>, C. Lapa<sup>2</sup>, A. Gaumann<sup>3</sup>, J. Veloso De Oliveira<sup>4</sup>, J. Scheiber<sup>5</sup>, P. Philipp<sup>4</sup>, C. Oyarzun<sup>6</sup>, S. Wesarg<sup>6</sup>, S. Robert<sup>7</sup>, D. Hempel<sup>8</sup>, <sup>1</sup>Sigmund Freud University Vienna, Vienna, AT, <sup>2</sup>University Hospital Augsburg, Augsburg, DE, <sup>3</sup>Molekularpathologie Suedbayern, Penzberg, DE, <sup>4</sup>Fraunhofer IOSB, Karlsruhe, DE, <sup>5</sup>BioVariance GmbH Waldsassen, Waldsassen, DE, <sup>6</sup>Fraunhofer IGD, Darmstadt, DE, <sup>7</sup>Technical University of Applied Sciences Rosenheim, Rosenheim, DE, <sup>8</sup>Institute of Translational Molecular Tumor Research, Freising, DE

- 20:00 - 20:20 **37P - Retrospective analysis of real-world data to evaluate actionability of a large molecular profiling panel in solid tumors (REALM study)**  
K. Leroy<sup>1</sup>, C. Audigier Valette<sup>2</sup>, S. Galoin<sup>1</sup>, A. Civet<sup>1</sup>, A. Italiano<sup>3</sup>, <sup>1</sup>Roche S.A.S, Boulogne-Billancourt, FR, <sup>2</sup>Hopital Sainte Musse, Toulon, FR, <sup>3</sup>Institute Bergonié, Bordeaux, FR
- 20:20 - 20:40 **38P - New tetraamide compounds targeting BCSCs from chemoresistant basal-like TNBC subtypes**  
A. Sevillano Chapartegui<sup>1</sup>, M. Rodriguez<sup>2</sup>, M. Costas<sup>2</sup>, X. Ribas<sup>2</sup>, S. Ruiz-Martinez<sup>3</sup>, T. Puig<sup>3</sup>, <sup>1</sup>University of Girona, Girona, ES, <sup>2</sup>Institut de Química Computacional iCatàlisi (IQCC), University of Girona, Girona, ES, <sup>3</sup>New Therapeutic Targets Laboratory (TargetsLab) Oncology Unit, University of Girona, Girona, ES
- 20:40 - 21:00 **39P - OLIMPIA dataset: radiomics to predict outcomes in EGFR-mutant non-small cell lung cancer**  
G. Pérez<sup>1</sup>, J.N. Minatta<sup>2</sup>, M. Aineseder<sup>1</sup>, C. Mosquera<sup>1</sup>, S. Benitez<sup>1</sup>, <sup>1</sup>Hospital Italiano de Buenos Aires, Ciudad Autónoma de Buenos Aires, AR, <sup>2</sup>Hospital Italiano de Buenos Aires, Buenos Aires, AR
- 21:00 - 21:20 **40P - Real-World Clinical Genomic Analysis of Patients with BRAF Mutated Cancers Identifies BRAF Class II and III as a Population of Unmet Medical Need**  
P. Severson<sup>1</sup>, W. Kellner<sup>2</sup>, A. Franovic<sup>1</sup>, N. Miller<sup>1</sup>, E. Murphy<sup>1</sup>, E. Martin<sup>1</sup>, R. Williams<sup>1</sup>, <sup>1</sup>Kinnate Biopharma Inc., San Diego, US, <sup>2</sup>Tempus Labs, Chicago, US
- 21:20 - 21:40 **41P - The SARS-CoV-2 vaccine and enrollment of patients with cancer in Phase I trials: the experience at Institute Gustave Roussy**  
L. Belcaid<sup>1</sup>, C. Baldini<sup>2</sup>, A. Laparra<sup>2</sup>, <sup>1</sup>Copenhagen University Hospital, Rigshospitalet, DK, <sup>2</sup>Institut Gustave Roussy, Villejuif, Cedex, FR
- 21:40 - 22:00 **42P - BAL0891: a novel, small molecule, dual TTK/PLK1 mitotic checkpoint inhibitor (MCI) with potent single agent activity**  
H. Lane<sup>1</sup>, E. Zanini<sup>2</sup>, N. Forster-Gross<sup>2</sup>, K. Litherland<sup>3</sup>, F. Bachmann<sup>3</sup>, L. Bury<sup>3</sup>, N. Willemsem-Seegers<sup>4</sup>, J. De Man<sup>4</sup>, D. Vu-Pham<sup>4</sup>, W. Van Riel<sup>4</sup>, G. Zaman<sup>4</sup>, R. Buijsman<sup>4</sup>, A. Groner<sup>3</sup>, M. Roceri<sup>3</sup>, K. Burger<sup>3</sup>, P. Mcsheehy<sup>3</sup>, L. Kellenberger<sup>3</sup>, <sup>1</sup>Basilea Pharmaceutica Ltd., Basel, CH, <sup>2</sup>Basilea Pharmaceutica Int Ltd., Basel, CH, <sup>3</sup>Basilea Pharmaceutica Int Ltd, Basel, CH, <sup>4</sup>NTRC B.V., Oss, NL
- 22:00 - 22:20 **43P - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy**  
T. Leal<sup>1</sup>, D. Berz<sup>2</sup>, I. Rybkin<sup>3</sup>, W. Iams<sup>4</sup>, D. Bruno<sup>5</sup>, C. Blakely<sup>6</sup>, A. Spira<sup>7</sup>, M. Patel<sup>8</sup>, D.M. Waterhouse<sup>9</sup>, D. Richards<sup>10</sup>, A. Pham<sup>11</sup>, R. Jotte<sup>12</sup>, E. Garon<sup>13</sup>, D. Hong<sup>14</sup>, R. Shazer<sup>15</sup>, X. Yan<sup>16</sup>, L. Latven<sup>16</sup>, K. He<sup>17</sup>, <sup>1</sup>Emory University, Atlanta, US, <sup>2</sup>Beverly Hills Cancer Center, Beverly Hills, US, <sup>3</sup>Henry Ford Cancer Institute, Detroit, US, <sup>4</sup>Vanderbilt-Ingram, Nashville, US, <sup>5</sup>University Hospitals Seidman Cancer Center, Cleveland, US, <sup>6</sup>University

of California San Francisco, San Francisco, US, <sup>7</sup>Virginia Cancer Specialist, Fairfax, US, <sup>8</sup>University of Minnesota Masonic Cancer Center, Minneapolis, US, <sup>9</sup>OHC, Cincinnati, US, <sup>10</sup>Texas Oncology-Tyler Medical Records Coordinator, Tyler, US, <sup>11</sup>Northwest Cancer Specialists, Portland, US, <sup>12</sup>Rocky Mountain Cancer Center, US Oncology Research, Denver, US, <sup>13</sup>UCLA Hematology/Oncology Santa Monica, Santa Monica, US, <sup>14</sup>MD Anderson Cancer Center, The University of Texas, Houston, US, <sup>15</sup>TRACON Pharmaceuticals, Inc., San Diego, US, <sup>16</sup>Mirati Therapeutics, San Diego, US, <sup>17</sup>Comprehensive Cancer Center, The Ohio State University, Columbus, US

22:20 - 22:40

**44P - A first-in-human, open-label, dose-escalation study to investigate the safety and tolerability of CHC2014, a tropomyosin receptor kinase (TRK) inhibitor, in adult patients with advanced solid tumors**

T. Yun<sup>1</sup>, S.J. Shin<sup>2</sup>, D.-W. Kim<sup>3</sup>, C.H. Yun<sup>4</sup>, S. Heo<sup>5</sup>, B. Hyun<sup>4</sup>, Y.S. Kim<sup>6</sup>, J.S. Kim<sup>7</sup>, Y.W. Moon<sup>8</sup>, <sup>1</sup>National Cancer Center Hospital, Goyang, KR, <sup>2</sup>Yonsei University College of Medicine, Seoul, KR, <sup>3</sup>SNUH - Seoul National University Hospital, Seoul, KR, <sup>4</sup>Handok Inc., Seoul, KR, <sup>5</sup>Handok, Inc., Seoul, KR, <sup>6</sup>CMG Pharmaceutical Co., Ltd., Seoul, KR, <sup>7</sup>CMG Pharmaceutical Co., Ltd., Seongnam, KR, <sup>8</sup>Bundang Cha Medical Center, Seongnam, KR

22:40 - 23:00

**45P - Alofanib in subsequent therapy of advanced gastric cancer: Final results from the phase Ib clinical trial**

L. Vladimirova<sup>1</sup>, V. Kurakin<sup>2</sup>, N. Besova<sup>3</sup>, G. Statsenko<sup>2</sup>, A. Mochalova<sup>4</sup>, N. Trenina<sup>5</sup>, E. Artamonova<sup>6</sup>, K. Novoselova<sup>1</sup>, T. Titova<sup>3</sup>, N. Abramova<sup>7</sup>, E. Obarevich<sup>6</sup>, A. Kashanova<sup>4</sup>, M. Suetina<sup>8</sup>, I. Agranov<sup>9</sup>, S. Iugai<sup>10</sup>, G. Raskin<sup>11</sup>, V. Kazey<sup>12</sup>, I. Rykov<sup>13</sup>, S. Tjulandin<sup>6</sup>, I. Tsimafeyeu<sup>14</sup>, <sup>1</sup>National Medical Research Centre for Oncology, Rostov-on-Don, RU, <sup>2</sup>OMSK Regional Oncology Center, Omsk, RU, <sup>3</sup>N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, <sup>4</sup>Medsi, Moscow, RU, <sup>5</sup>Omsk Regional Oncology Center, Omsk, RU, <sup>6</sup>National Medical Research Center of Oncology named after N.N. Blokhin, Moscow, RU, <sup>7</sup>Rostov Research Institute of Oncology, Rostov-on-Don, RU, <sup>8</sup>MEDSI GROUP - Medsi Clinic in Botkinsky Passage, Moscow, RU, <sup>9</sup>St. Petersburg Clinical and Research Center of Specialized Types of Medical Care (Oncological), St. Petersburg, RU, <sup>10</sup>Saint Petersburg Clinical Hospital of Russian Academy of Sciences., Saint Petersburg, RU, <sup>11</sup>Republican Clinical Oncological Dispensary of Tatarstan Republic, Kazan, RU, <sup>12</sup>Exacte Labs, Moscow, RU, <sup>13</sup>St. Petersburg Clinical Hospital of the Russian Academy of Sciences, Saint-Petersburg, RU, <sup>14</sup>Institute of Oncology, Hadassah Moscow, Moscow, RU

23:00 - 23:20

**46P - AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2 $\alpha$  Inhibitor, for the Treatment of Renal Cell Carcinoma**

K. Lawson, K. Sivick Gauthier, D. Piovesan, A. Mailyan, G. Mata, J. Fournier, K. Yu, S. Liu, F. Soriano, L. Jin, E. Ginn, P. Schweickert, C. Meleza, A. Pham, L. Seitz, K. Liao, E. Paterson, P. Foster, M. Walters, M. Leleti, Arcus Biosciences, Inc., Hayward, US

23:20 - 23:40

**47P - Prevalence of mutations in common tumour types in Northern England and utility of Experimental Cancer Medicine Centre (ECMC) CRUK Trial Finder**

S. Rae<sup>1</sup>, E. Plummer<sup>2</sup>, L. Fitzgerald<sup>2</sup>, L. Hogarth<sup>2</sup>, A. Bridgewood<sup>2</sup>, L. Brown-Schofield<sup>2</sup>, J. Graham<sup>2</sup>, Y. Drew<sup>2</sup>, N. Haris<sup>2</sup>, S. Bashir<sup>2</sup>, R. Plummer<sup>3</sup>, A. Greystoke<sup>2</sup>, <sup>1</sup>Newcastle University, Newcastle upon Tyne, GB, <sup>2</sup>The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, <sup>3</sup>Newcastle University, Newcastle-upon-Tyne, GB



- 23:40 - 00:00 **48P - (Withdrawn)**
- 00:00 - 00:20 **49P - Antitumor effects of cationic dendritic molecules and their complexes with microRNA in glioblastoma stem-like cells**  
N. Knauer<sup>1</sup>, E. Pashkina<sup>1</sup>, V. Kozlov<sup>1</sup>, R. Gomez<sup>2</sup>, A.-M. Caminade<sup>3</sup>, U. Kahlert<sup>4</sup>, E. Apartsin<sup>3</sup>, <sup>1</sup>FSBSI Research Institute of Fundamental and Clinical Immunology, Novosibirsk, RU, <sup>2</sup>University of Alcalá, Alcalá de Henares, ES, <sup>3</sup>Laboratory of Coordinational Chemistry CNRS, Toulouse, FR, <sup>4</sup>Otto-von-Guericke-University Magdeburg, Magdeburg, DE
- 00:20 - 00:40 **50P - Targeting the renin-angiotensin system in gastric cancer therapeutics**  
S. Chimed, Sor clinic, Ulaanbaatar, MN
- 00:40 - 01:00 **51P - Mitochondrial Pro-Apoptotic Properties of isolated compounds from two soft corals of Persian Gulf**  
A. Yegdaneh, Isfahan University of Medical Sciences, Isfahan, IR
- 01:00 - 01:20 **52P - Novel inhibitors of androgen receptor with antiproliferative potency against hormone-sensitive and hormone-resistant breast cancer cells**  
A. Scherbakov<sup>1</sup>, S. Krymov<sup>2</sup>, D. Sorokin<sup>3</sup>, D. Salnikova<sup>4</sup>, A. Shchekotikhin<sup>5</sup>, <sup>1</sup>N.N. Blokhin National Medical Research Center of Oncology, Moscow, RU, <sup>2</sup>FSBI Gause Institute of New Antibiotics, Moscow, RU, <sup>3</sup>Blokhin N.N. National Medical Research Center of Oncology, Moscow, RU, <sup>4</sup>Lomonosov Moscow State University, Moscow, RU, <sup>5</sup>Gause Institute of New Antibiotics, Moscow, RU
- 01:20 - 01:40 **General interest**
- 01:40 - 02:00 **53P - Assessing the reporting quality of early phase dose-finding trials**  
C. Yap<sup>1</sup>, O. Solovyeva<sup>2</sup>, Z. Yin<sup>2</sup>, J. Martin<sup>2</sup>, T. Manickavasagar<sup>2</sup>, C. Weir<sup>3</sup>, S. Lee<sup>4</sup>, M. Dimairo<sup>5</sup>, R. Liu<sup>6</sup>, A. Kightley<sup>7</sup>, J. De Bono<sup>8</sup>, <sup>1</sup>ICR - The Institute of Cancer Research - North Site, Sutton, GB, <sup>2</sup>The Institute of Cancer Research, NG, GB, <sup>3</sup>University of Edinburgh, UX, GB, <sup>4</sup>Columbia University, New York, US, <sup>5</sup>University of Sheffield, Sheffield, GB, <sup>6</sup>Bristol Myers Squibb, New York, US, <sup>7</sup>Patient and Public involvement partner, Lichfield, GB, <sup>8</sup>ICR - Institute of Cancer Research, London, GB
- 02:00 - 02:20 **54P - Targeted treatment options for childhood hepatoblastoma using high-throughput drug screening**  
R. Nousiainen<sup>1</sup>, K. Eloranta<sup>2</sup>, A. Hassinen<sup>3</sup>, J. Saarela<sup>3</sup>, S. Cairo<sup>4</sup>, V. Pietiäinen<sup>3</sup>, M. Heikinheimo<sup>2</sup>, M. Pihlajoki<sup>2</sup>, <sup>1</sup>University of Helsinki - Faculty of medicine, Helsinki, FI, <sup>2</sup>University of Helsinki, Helsinki, FI, <sup>3</sup>Institute for Molecular Medicine Finland (FIMM), Helsinki, FI, <sup>4</sup>XenTech, Evry, FR
- 02:20 - 02:40 **55P - Potential benefits of extensive genomic analysis in patients with KRAS mutated solid tumors; concurrent alterations and potential targets**

I. Jacobsen<sup>1</sup>, I. Spanggaard<sup>2</sup>, M. Hoejgaard<sup>3</sup>, L. Belcaid<sup>4</sup>, C. Qvortrup<sup>3</sup>, C. Yde<sup>2</sup>, A. Schmidt<sup>2</sup>, F. Nielsen<sup>2</sup>, G. Willemoe<sup>2</sup>, M. Dam<sup>2</sup>, U. Lassen<sup>3</sup>, K. Rohrberg<sup>3</sup>, <sup>1</sup>University of Copenhagen - Faculty of Health and Medical Sciences, Copenhagen, DK, <sup>2</sup>Rigshospitalet, University Hospital of Copenhagen, Copenhagen, DK, <sup>3</sup>Rigshospitalet, Copenhagen, DK, <sup>4</sup>Copenhagen University Hospital, Rigshospitalet, DK

02:40 - 03:00 **56P - An Institutional study evaluating the benefit of blood NGS over conventional hotspot molecular genetic testing in metastatic adenocarcinoma lung.**

R. Ashwath, Manipal Comprehensive Cancer Center Manipal Hospital, Bangalore, IN

**12:25 - 13:00 Welcome to ESMO TAT 2022 and Honorary award Channel 1**

Moderation: R. Plummer<sup>1</sup>, L. Siu<sup>2</sup>, <sup>1</sup>Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup>Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, Toronto, CA

12:25 - 12:30 **Welcome to ESMO TAT 2022**

R. Plummer<sup>1</sup>, L. Siu<sup>2</sup>, <sup>1</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup>Princess Margaret Cancer Centre, Toronto, CA

12:30 - 12:35 **Introduction to the ESMO TAT 2022 Honorary award**

R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

12:35 - 13:00 **TAT 2022 Honorary award keynote lecture**

**13:00 - 14:00 Daiichi Sankyo/AstraZeneca - From bench to bedside and back to bench: The evolution of antibody-drug conjugates in the treatment of cancer Channel 2**

Moderation: S. Peters, Oncology Dept., CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

13:00 - 13:20 **Introduction**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

13:20 - 13:40 **Round-table discussion**

M. Peipp<sup>1</sup>, A. Prat<sup>2</sup>, S. Peters<sup>3</sup>, <sup>1</sup>Christian-Albrechts-University Kiel, Kiel, DE, <sup>2</sup>Hospital Clinic y Provincial de Barcelona, Barcelona, ES, <sup>3</sup>CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

13:40 - 14:00 **Q&A and closing remarks**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

**13:15 - 14:00 How reliable are the scientific data? Channel 1**

Moderation: L. Ellis<sup>1</sup>, E.G.E. De Vries<sup>2</sup>, <sup>1</sup>Surgical Oncology Dept., University of Texas MD Anderson Cancer Center, Houston, US, <sup>2</sup>Medical Oncology Department, UMCG - University Medical Center Groningen, Groningen, NL

**13:15 - 13:35 Presentation**

E.G.E. De Vries<sup>1</sup>, L. Ellis<sup>2</sup>, <sup>1</sup>UMCG - University Medical Center Groningen, Groningen, NL, <sup>2</sup>University of Texas MD Anderson Cancer Center, Houston, US

**13:35 - 14:00 Live Q&A and discussion**

**14:15 - 15:30 Molecular imaging for personalised medicine Channel 2**

Moderation: E.G.E. De Vries<sup>1</sup>, L. Siu<sup>2</sup>, <sup>1</sup>Medical Oncology Department, UMCG - University Medical Center Groningen, Groningen, NL, <sup>2</sup>Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, Toronto, CA

**14:15 - 14:30 PET-based next generation molecular imaging**

A. Rominger, University of Bern, Bern, CH

**14:30 - 14:45 PET/CT to select for and guide radioligand therapies**

M. Hofman, Victorian Comprehensive Cancer Centre, Melbourne, AU

**14:45 - 15:00 Molecular imaging of immune checkpoints, immune cells and CAR-T cells for profiling tumour heterogeneity and selecting immunotherapy**

E.G.E. De Vries, UMCG - University Medical Center Groningen, Groningen, NL

**15:00 - 15:15 Imaging therapeutic targets and drug engagement: Steroid receptors and PARP**

D. Mankoff, Abramson Cancer Center - University of Pennsylvania, Philadelphia, US

**15:15 - 15:30 Live Q&A and discussion**

<b>14:15 - 15:30</b>	<b>Bispecifics and T-cell engagers</b>	<b>Channel 1</b>
	Moderation: A. Greystoke <sup>1</sup> , H. Van Der Vliet <sup>2</sup> , <sup>1</sup> Medical Oncology Department, The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB, <sup>2</sup> Medical Oncology Dept, Vrije University Medical Centre (VUMC), Amsterdam, NL	
14:15 - 14:35	<b>Redirecting T-cells to kill cancer cells: Lessons learnt from CD3 BiTEs</b> <u>P. Baeuerle</u> , Cullinan Oncology, Cambridge, US	
14:35 - 14:55	<b>Bispecific gamma-delta T-cell engagers for the treatment of cancer</b> <u>H. Van Der Vliet</u> , Vrije University Medical Centre (VUMC), Amsterdam, NL	
14:55 - 15:15	<b>Targeting resistance-driving actionable mutations with bispecific antibodies</b> <u>J. Sabari</u> , NYU Langone Health - Perlmutter Cancer Center - 34th Street, New York, US	
15:15 - 15:30	<b>Live Q&amp;A and discussion</b>	
<b>15:45 - 17:00</b>	<b>Early talent in early phase development</b>	<b>Channel 2</b>
	Moderation: R. Plummer <sup>1</sup> , L. Siu <sup>2</sup> , <sup>1</sup> Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup> Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, Toronto, CA	
15:45 - 16:00	<b>Novel immunotherapies in breast cancer</b> <u>M. Kok</u> , Netherlands Cancer Institute, Amsterdam, NL	
16:00 - 16:15	<b>Interventional studies on therapeutic microbiome manipulation</b> <u>A. Spreafico</u> , Princess Margaret Cancer Center, Toronto, CA	
16:15 - 16:30	<b>Emerging combination strategies combining DDR and RT in NSCLC</b> <u>A. Greystoke</u> , The Freeman Hospital (NHS Foundation Trust) Northern Centre for Cancer Care, Newcastle-upon-Tyne, GB	
16:30 - 16:45	<b>Breakthrough research combining ctDNA and computational biology</b> <u>I. Cortes-Ciriano</u> , EMBL-EBI - European Bioinformatics Institute, Hinxton, GB	
16:45 - 17:00	<b>Live Q&amp;A and discussion</b>	

**15:45 - 17:00 Cellular therapy beyond CART Channel 1**

Moderation: J. Haanen<sup>1</sup>, A. Stathis<sup>2</sup>, <sup>1</sup>Medical Oncology Dept, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL, <sup>2</sup>Medical Oncology Department, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH

**15:45 - 16:00 Next generation genome editing for enabling allogeneic cell products**

Q. Waseem, UCL Great Ormond Street Institute of Child Health, London, GB

**16:00 - 16:15 New developments in tumour infiltrating lymphocyte (TIL) therapy**

J. Haanen, Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital (NKI-AVL), Amsterdam, NL

**16:15 - 16:30 T-cell receptor (TCRs)-based approaches to target solid tumours**

T. Blankenstein, Max Delbrück Center for Molecular Medicine MDC, Berlin, DE

**16:30 - 16:45 Looking beyond T-cells: NK cells as effectors of tumour control**

U. Köhl, Fraunhofer Institute for Cell Therapy and Immunology, Leipzig, DE

**16:45 - 17:00 Live Q&A and discussion****17:15 - 18:20 Mini oral session Channel 1**

Moderation: K. Dhingra<sup>1</sup>, G. Shapiro<sup>2</sup>, <sup>1</sup>KAPital Consulting LLC,, New York, US, <sup>2</sup>Medical Oncology, Dana Farber Cancer Institute, Boston, US

**17:15 - 17:20 5MO - Comprehensive dose-finding strategy for single-agent RP-3500, a highly selective inhibitor of ataxia telangiectasia and Rad3-related (ATR) kinase**

E. Fontana<sup>1</sup>, E. Lee<sup>2</sup>, E. Rosen<sup>3</sup>, D. Spigel<sup>4</sup>, M. Højgaard<sup>5</sup>, S. Lheureux<sup>6</sup>, N. Mettu<sup>7</sup>, L. Carter<sup>8</sup>, R. Plummer<sup>9</sup>, P. Manley<sup>10</sup>, D. Ulanet<sup>10</sup>, V. Rimkunas<sup>10</sup>, I. Silverman<sup>10</sup>, J. O'Connell<sup>10</sup>, R. Mcdougall<sup>10</sup>, M. Wainszelbaum<sup>10</sup>, Y. Xu<sup>10</sup>, M. Koehler<sup>10</sup>, A. Fretland<sup>10</sup>, T. Yap<sup>11</sup>, <sup>1</sup>Sarah Cannon Research Institute UK, London, GB, <sup>2</sup>Dana-Farber Cancer Institute, Boston, US, <sup>3</sup>Memorial Sloan Kettering Cancer Center, New York, US, <sup>4</sup>Sarah Cannon Research Institute, Nashville, US, <sup>5</sup>Rigshospitalet, Copenhagen, DK, <sup>6</sup>University Health Network - Princess Margaret Cancer Center, Toronto, CA, <sup>7</sup>Duke University Medical Center, Durham, US, <sup>8</sup>Institution The Christie NHS Foundation Trust, Manchester, GB, <sup>9</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>10</sup>Repare Therapeutics, Cambridge, US, <sup>11</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US

**17:20 - 17:25 6MO - Translational relevance of the combined treatment PARP inhibitors and AsiDNA in homologous recombination proficient tumors**

W. Jdey<sup>1</sup>, V. Trochon-Joseph<sup>1</sup>, C. Doizelet<sup>2</sup>, V. Hayes<sup>2</sup>, A. Cohendet<sup>1</sup>, M.-C. Lienafa<sup>1</sup>, C. Zandanel<sup>1</sup>, O. De Beaumont<sup>2</sup>, J. Miara<sup>3</sup>, <sup>1</sup>Onxeo, Paris, FR, <sup>2</sup>ONXEO, Paris, FR, <sup>3</sup>The Invus Group, LLC, Paris, FR

- 17:25 - 17:30 **7MO - WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in small cell lung cancer**  
T. Sen, Memorial Sloan Kettering Cancer Center, New York, US
- 17:30 - 17:40 **Invited Discussant of abstracts 5MO, 6MO and 7MO**  
G. Shapiro, Dana Farber Cancer Institute, Boston, US
- 17:40 - 17:50 **Live Q&A and discussion**
- 17:50 - 17:55 **26MO - Efficacy and safety of poziotinib in treatment-naïve HER2 exon 20 insertion (ex20ins) mutated non-small cell lung cancer (NSCLC): ZENITH20-4**  
S. Sun<sup>1</sup>, A. Prelaj<sup>2</sup>, C. Baik<sup>3</sup>, X. Le<sup>4</sup>, M. Garassino<sup>5</sup>, M. Wollner<sup>6</sup>, E. Haura<sup>7</sup>, Z. Piotrowska<sup>8</sup>, M. Socinski<sup>9</sup>, L. Dreiling<sup>10</sup>, G. Bhat<sup>10</sup>, F. Lebel<sup>10</sup>, R. Cornelissen<sup>11</sup>, <sup>1</sup>BC Cancer Agency - Vancouver, Vancouver, CA, <sup>2</sup>Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, IT, <sup>3</sup>Seattle Cancer Care Alliance, Seattle, US, <sup>4</sup>UT MD Anderson Cancer Center, Houston, US, <sup>5</sup>Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT, <sup>6</sup>Rambam Healthcare Campus, Haifa, IL, <sup>7</sup>H. Lee Moffitt Cancer Center & Research Institute, Tampa, US, <sup>8</sup>Massachusetts General Hospital, Boston, US, <sup>9</sup>Florida Hospital Cancer Institute, Orlando, US, <sup>10</sup>Spectrum Pharmaceuticals, Irvine, US, <sup>11</sup>Erasmus MC - University Medical Center, Rotterdam, NL
- 17:55 - 18:00 **27MO - BDTX-1535, a CNS penetrant, irreversible inhibitor of intrinsic and acquired resistance EGFR mutations, demonstrates preclinical efficacy in NSCLC and GBM PDX models.**  
M. Lucas<sup>1</sup>, M. Merchant<sup>2</sup>, M. O'Connor<sup>1</sup>, S. Smith<sup>2</sup>, A. Trombino<sup>2</sup>, W.-Y. Zhang<sup>2</sup>, J. Simon<sup>2</sup>, S. Eathiraj<sup>2</sup>, N. Waters<sup>2</sup>, E. Buck<sup>1</sup>, <sup>1</sup>Black Diamond Therapeutics, New York, US, <sup>2</sup>Black Diamond Therapeutics, Cambridge, US
- 18:00 - 18:10 **Invited Discussant of abstracts 26MO and 27MO**  
K. Dhingra, KAPital Consulting LLC,, New York, US
- 18:10 - 18:20 **Live Q&A and discussion**

**18:35 - 19:20 How to move forward an investigator initiated trial: Tips and tricks Channel 2**

Moderation: T. Yap<sup>1</sup>, R. Plummer<sup>2</sup>, <sup>1</sup>Investigational Cancer Therapeutics Dept. (phase I Program), The University of Texas M. D. Anderson Cancer Center, Houston, US, <sup>2</sup>Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB

**18:35 - 18:55 Presentation**

R. Plummer<sup>1</sup>, T. Yap<sup>2</sup>, <sup>1</sup>Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup>The University of Texas M. D. Anderson Cancer Center, Houston, US

**18:55 - 19:20 Live Q&A and discussion****18:35 - 19:20 How to write a grant Channel 1**

Moderation: J. De Bono<sup>1</sup>, C. Yap<sup>2</sup>, <sup>1</sup>ICR - Institute of Cancer Research, London, GB, <sup>2</sup>Clinical Trials Biostatistics Department, ICR - The Institute of Cancer Research - North Site, Sutton, GB

**18:35 - 18:55 Presentation**

J. De Bono<sup>1</sup>, C. Yap<sup>2</sup>, <sup>1</sup>ICR - Institute of Cancer Research, London, GB, <sup>2</sup>ICR - The Institute of Cancer Research - North Site, Sutton, GB

**18:55 - 19:20 Live Q&A and discussion**

08.03.2022

**12:00 - 12:45 The industry perspective on optimal selection of drugs to take into the clinic** **Channel 2**  
Moderation: J.-C. Soria, AMGEN (Headquarters) - USA, Thousand Oaks, US

12:00 - 12:20 **Presentation**  
J.-C. Soria, AMGEN (Headquarters) - USA, Thousand Oaks, US

12:20 - 12:45 **Live Q&A and discussion**

**12:00 - 12:45 How to write, peer review and publish a manuscript** **Channel 1**  
Moderation: S. Bates<sup>1</sup>, L. Seymour<sup>2</sup>, <sup>1</sup>Medicine Hematology/medical Oncology Department, Columbia University, New York, US, <sup>2</sup>Ind Program, Canadian Cancer Trials Group, Kingston, CA

12:00 - 12:20 **Presentation**  
S. Bates<sup>1</sup>, L. Seymour<sup>2</sup>, <sup>1</sup>Columbia University, New York, US, <sup>2</sup>Canadian Cancer Trials Group, Kingston, CA

12:20 - 12:45 **Live Q&A and discussion**

**13:00 - 13:30 Keynote lecture** **Channel 1**  
Moderation: R. Plummer, Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB

13:00 - 13:05 **Introduction to the Keynote lecture**  
R. Plummer, Newcastle University, Newcastle-upon-Tyne, GB

13:05 - 13:30 **Current clinical, molecular and immunological landscapes of breast cancer and future directions**  
F. André, Gustave Roussy - Cancer Campus, Villejuif, FR





**13:45 - 15:00 Oral immuno-oncology agents** **Channel 2**  
 Moderation: I. Melero<sup>1</sup>, L. Zitvogel<sup>2</sup>, <sup>1</sup>Laboratory Of Immunology, Clinica Universitaria de Navarra, Pamplona, ES, <sup>2</sup>Institut Gustave Roussy, Villejuif, FR

13:45 - 14:00 **Acting on the prostaglandin pathway**  
S. Zelenay, Cancer Research UK Manchester Institute, Manchester, GB

14:00 - 14:15 **Acting on the extracellular adenosine pathway**  
I. Melero, Clinica Universitaria de Navarra, Pamplona, ES

14:15 - 14:30 **Acting on gut microbiota**  
L. Zitvogel, Institut Gustave Roussy, Villejuif, FR

14:30 - 14:45 **Small molecule drug discovery in immunotherapy**  
R. Offringa, German Cancer Research Center, Heidelberg, DE

14:45 - 15:00 **Live Q&A and discussion**

**13:45 - 15:00 Optimising kinase inhibitors** **Channel 1**  
 Moderation: U. Banerji<sup>1</sup>, E. Garralda<sup>2</sup>, <sup>1</sup>Drug Development Unit , The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB, <sup>2</sup>Early Drug Development Group, Vall d'Hebron University Hospital, Barcelona, ES

13:45 - 14:00 **The convergence of potency, selectivity and tumour biology: Inhibitors of NTRK, MET and RET**  
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

14:00 - 14:15 **Broad spectrum and mutant-selective kinase inhibitor development for imatinib-resistant GIST**  
S. Bauer, University Hospital Essen Westdeutsches Tumorzentrum, Essen, DE

14:15 - 14:30 **Structural biology and precision targeting of RTK/RAS/MAPK inhibitors**  
E. Garralda, Vall d'Hebron University Hospital, Barcelona, ES

14:30 - 14:45 **Challenges in the development of brain-penetrant kinase inhibitors**  
N. Steeghs, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

14:45 - 15:00 **Live Q&A and discussion**

**15:15 - 16:30 COVID and drug development Channel 2**  
 Moderation: E. Calvo<sup>1</sup>, S. Postel-Vinay<sup>2</sup>, <sup>1</sup>Dept. Early Clinical Drug Development, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES, <sup>2</sup>Drug Development Department, Institut Gustave Roussy, Villejuif, FR

15:15 - 15:30 **Trends in oncology clinical trials before and during the pandemic**  
D. Araujo, Hospital de Base de Sao Jose do Rio Preto, Sao Jose do Rio Preto, BR

15:30 - 15:45 **Early clinical trial management during the COVID-19 pandemic**  
E. Calvo, Hospital Madrid Norte San Chinarro - Centro Integral Oncologico Clara Campal, Madrid, ES

15:45 - 16:00 **COVID-19 pandemic: Impact on clinical trials and measures implemented to sustain activity**  
A. Bayle, Hopital Europeen Georges-Pompidou - APHP, Paris, FR

16:00 - 16:15 **SARS-CoV-2 vaccination and cancer clinical trials**  
U. Banerji, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, GB

16:15 - 16:30 **Live Q&A and discussion**

**15:15 - 16:30 Protein degradation Channel 1**  
 Moderation: S. Alabi<sup>1</sup>, P. Lorusso<sup>2</sup>, <sup>1</sup>Yale University, New Haven, US, <sup>2</sup>Medical Oncology, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US

15:15 - 15:35 **Overview of protein degraders**  
S. Alabi, Yale University, New Haven, US

15:35 - 15:55 **Protein degraders: Therapeutic potential for solid tumour therapies**  
A. Pandiella, Universidad de Salamanca (USAL) - 3 Instituto de Biología Molecular y Celular del Cáncer (IBMCC), Salamanca, ES

15:55 - 16:15 **Protein degraders: Molecular mechanisms and therapeutic potential for targeting cancer**  
A. Ciulli, University of Dundee, Dundee, GB

16:15 - 16:30 **Live Q&A and discussion**

**16:45 - 18:00 Antibody-drug conjugates (ADCs) Channel 1**

Moderation: F. André<sup>1</sup>, A. Bardia<sup>2</sup>, <sup>1</sup>Breast Cancer Unit, Medical Oncology Department, Gustave Roussy - Cancer Campus, Villejuif, FR, <sup>2</sup>Medical Oncology Dept., Massachusetts General Hospital Cancer Center, Boston, US

**16:45 - 17:00 Biochemical and physical principles of ADC structure**

P. Sapra, University of Alberta, New York, US

**17:00 - 17:15 Mechanisms of action of ADCs: Preclinical and clinical**

G. Montagnac, Institut Gustave Roussy, Villejuif, FR

**17:15 - 17:30 Current state of the art on ADC therapeutic strategies**

A. Bardia, Massachusetts General Hospital Cancer Center, Boston, US

**17:30 - 17:45 A glimpse to the future: Moving towards combinations**

J. Drago, Memorial Sloan Kettering Cancer Center, New York, US

**17:45 - 18:00 Live conclusions: Can we move towards personalised ADCs?****16:45 - 18:00 Patient selection for synthetic lethality trials Channel 2**

Moderation: R. Plummer<sup>1</sup>, T. Yap<sup>2</sup>, <sup>1</sup>Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup>Investigational Cancer Therapeutics Dept. (phase I Program), The University of Texas M. D. Anderson Cancer Center, Houston, US

**16:45 - 17:00 Patient selection for single agent ATRi in the clinic**

J. De Bono, ICR - Institute of Cancer Research, London, GB

**17:00 - 17:15 Exploiting PARP synthetic lethality beyond germline BRCA mutations**

M. O'Connor, AstraZeneca R&D - Chesterford Research Park, Cambridge, GB

**17:15 - 17:30 Optimal patient selection for ATRi and PARPi combinations**

M. Koehler, Repare Therapeutics, Cambridge, US

**17:30 - 17:45 Clinical activity of DNA PKi single agent therapies**

P. Lorusso, Yale School of Medicine - Radiology and Biomedical Imaging, New Haven, US

**17:45 - 18:00 Live Q&A and discussion**



**18:15 - 18:35 Take home messages and close Channel 1**

Moderation: R. Plummer<sup>1</sup>, L. Siu<sup>2</sup>, <sup>1</sup>Translational And Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne, GB, <sup>2</sup>Medical Oncology And Hematology Department, Princess Margaret Cancer Centre, Toronto, CA

**18:15 - 18:35 TAT 2022 highlights**

A. Stathis, EOC - Ospedale Regionale Bellinzona e Valli - Istituto Oncologico della Svizzera Italiana (IOSI), Bellinzona, CH